Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19

NCT04895449 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
43
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Universitätsklinikum Hamburg-Eppendorf

Collaborators